Country artist Mark Chesnutt has canceled several concerts following a hospital stay earlier this week. The singer, known for hits like “Brother Jukebox,” was set to perform at an Alabama show on Thursday at the Raising Cane’s River Center in Baton Rouge, Louisiana, but became unwell before the performance.
A representative for Chesnutt shared that he was admitted to Baton Rouge General Hospital on Thursday morning after arriving for his concert in Alabama. It seems he’s dealing with low sodium levels and high blood pressure, although his condition is currently stable.
Unfortunately, this also means he’s missing the show in Baton Rouge as well as another scheduled concert on October 18th in New Mexico.
Chesnutt expressed his regret, stating, “Mark would like to apologize to the fans who came to see him in Baton Rouge and those who were scheduled to see him in Portales, New Mexico today. He hopes to return to perform in both cities soon,” according to his rep.
Whether this hospitalization will influence his future tour dates remains uncertain.
Chesnutt has faced health problems before. In 2024, he underwent emergency heart surgery that forced him to cancel shows. At the time, a statement on social media announced he was hospitalized due to heart health issues and had to have a quadruple bypass surgery, which obviously required him to cancel upcoming performances.
He emphasized his gratitude for the support he received, saying, “We send our love and gratitude to our family, friends, band, and fans for their understanding, prayers, and support. We look forward to seeing you all again at a honky-tonk near you.”
Later that month, he provided a positive update, sharing that he was recovering. In a post on Instagram, he mentioned the doctors had given him a “new heart” and that he was enjoying time at home with his family while looking forward to performing again soon. He touched on how much the well-wishes and prayers from fans meant to him, expressing gratitude for their support.
Chesnutt also had a brief hospitalization in November 2023 for medical evaluation, though the specifics of that evaluation are unclear.
